Site icon pharmaceutical daily

2019 Pipeline Review on Iron Deficiency Anemia (H1) – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “Iron
Deficiency Anemia – Pipeline Review, H1 2019”
drug pipelines
has been added to ResearchAndMarkets.com’s offering.

Iron Deficiency Anemia – Pipeline Review, H1 2019
provides comprehensive information on the therapeutics under development
for Iron Deficiency Anemia (Hematological Disorders), complete with
analysis by stage of development, drug target, mechanism of action
(MoA), route of administration (RoA) and molecule type.

The guide covers the descriptive pharmacological action of the
therapeutics, its complete research and development history and latest
news and press releases. The Iron Deficiency Anemia (Hematological
Disorders) pipeline guide also reviews of key players involved in
therapeutic development for Iron Deficiency Anemia and features dormant
and discontinued projects.

The guide covers therapeutics under Development by
Companies/Universities/Institutes, the molecules developed by Companies
in Pre-Registration, Phase III, Phase II and Preclinical stages are 3,
3, 2 and 4 respectively. Similarly, the Universities portfolio in
Preclinical stages comprises 1 molecule, respectively.

Iron Deficiency Anemia (Hematological Disorders) pipeline guide helps in
identifying and tracking emerging players in the market and their
portfolios, enhances decision making capabilities and helps to create
effective counter strategies to gain competitive advantage.

Scope

Reasons to Buy

Featured News & Press Releases

Companies Mentioned

For more information about this drug pipelines report visit https://www.researchandmarkets.com/r/m5598

Contacts

ResearchAndMarkets.com
Laura Wood, Senior Press Manager
press@researchandmarkets.com
For
E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call
1-800-526-8630
For GMT Office Hours Call +353-1-416-8900
Related
Topics: Hematological
Drugs

Exit mobile version